Longevity closes second fund at $22M

Longevity Fund closed its second fund at $22 million. The firm's Laura Deming told BioCentury that it plans to invest in eight to 10 companies, with investments focused on companies with "the potential to impact the human healthspan." Longevity's first fund closed at $4 million.

Two companies from Longevity's portfolio had news last week. Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) tacked $35 million on to its $151 million series B round, and Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization (see BioCentury Extra, Aug. 15 & BioCentury Extra, Aug. 17)...